13 September 2026
PureHealth Holding PJSC (ADX: PUREHEALTH), the largest healthcare group in the Middle East, announced on Friday 11 September 2026 that its British subsidiary Circle Health Group will take over selected laboratory operations from Unilabs Limited in the United Kingdom. The perimeter covers two dedicated hub laboratories in Euston and Cavendish Square in London, supported by a network of fully licensed laboratories across the country, serving Circle’s own network of more than 50 UK hospitals and an established base of more than 90 external healthcare clients. The announcement discloses no purchase price, no completion date and no regulatory conditions, and it covers selected operations and infrastructure rather than Unilabs Limited as a legal entity.
What exactly was announced
The buyer inside the group is Circle Health Group, the UK hospital business PureHealth acquired from Centene for USD 1.2 billion in a deal announced in August 2023 and completed in January 2024. Circle, not the Abu Dhabi parent, takes on the laboratories. The seller is Unilabs Limited, the British arm of the European diagnostics group Unilabs, which has been owned by Denmark’s A.P. Moller Holding since March 2022.
The laboratories provide pathology, histopathology, blood sciences, microbiology and specialist diagnostic services. PureHealth describes the result as an integrated diagnostics model: Circle hospitals get in-house laboratory capacity, and the laboratories keep serving their existing external clients across the United Kingdom.
Volumes come in two waves. Circle’s existing clinical activity gives the network a laboratory workload from day one, and, in the words of the release, additional eligible volumes are expected to transition over time. The company does not quantify either wave.
By utilising PureLab’s proven diagnostics capabilities across Circle Health Group’s leading hospital network, we are creating an integrated model that strengthens every stage of the patient journey, from diagnosis through to treatment, said Shaista Asif, Group Chief Executive Officer of PureHealth.
Paul Manning, Chief Executive Officer of Circle Health Group, framed the same move operationally: closer collaboration between clinicians and laboratory specialists, better operational responsiveness, and continuity of service for external healthcare partners.
What the announcement does not say
Four gaps matter for anyone reading this as a deal rather than as a press release.
- No value. Neither PureHealth nor Circle disclosed consideration. Nothing in the release allows the transaction to be sized.
- No dates. There is no completion date, no transition start and no end date for the migration of eligible volumes.
- No conditions. Regulatory approvals, competition clearance and licence transfers are not mentioned either way.
- No headcount and no laboratory count. The release names the two London hubs but does not say how many laboratories sit in the national network, nor what happens to the staff running them.
What the release does confirm is the shape of the transaction: a carve out of selected operations and infrastructure, not a purchase of the Unilabs UK company. That distinction matters because it sets which contracts, licences and assets move and which stay.
Key parameters at a glance
| Parameter | Disclosed position |
|---|---|
| Announcement date | Friday 11 September 2026, PureHealth press release |
| Acquiring entity | Circle Health Group, UK subsidiary of PureHealth |
| Selling entity | Unilabs Limited, UK |
| Perimeter | Selected UK laboratory operations and infrastructure |
| London hubs | Euston and Cavendish Square |
| Internal demand base | More than 50 Circle hospitals in the UK |
| External clients retained | More than 90 healthcare clients |
| Service lines | Pathology, histopathology, blood sciences, microbiology, specialist diagnostics |
| Deal value | Not disclosed |
| Completion date | Not disclosed |
The UAE side of the story: PureLab
The operational argument for the deal sits in Abu Dhabi, not in London. PureLab, the group’s laboratory business in the UAE, manages more than 150 laboratories and processes over 25 million tests a year, which PureHealth describes as the largest laboratory network in the country. The release says PureLab’s automation, AI enabled diagnostics and internationally accredited laboratory systems will support the new UK platform, and that experience from the UK is expected to flow back into the group’s UAE operations.
That is a claim about capability transfer, not a commitment with a schedule attached. No target has been published for the number of UK laboratories to be converted to PureLab standards, and no date has been given for any of it.
Where this sits in PureHealth’s international platform
The group has been building an overseas portfolio for several years, and the financial effect is now visible in its accounts. In H1 2026 PureHealth reported revenue of AED 14.9 billion, up 9.4 per cent year on year, EBITDA of AED 2.9 billion, up 23.9 per cent, an EBITDA margin of 19.3 per cent, and net profit of AED 1.2 billion, up 20.1 per cent. The consolidation of Hellenic Healthcare Group, the hospital operator in Greece and Cyprus, contributed AED 1.6 billion of revenue in the half.
Alongside Circle in the UK and Hellenic in Greece and Cyprus, PureHealth’s own portfolio page lists Ardent Health Services in the United States, with 30 hospitals and more than 200 care sites across six states. Domestically the group holds Daman, the UAE’s largest health insurer with more than 3 million members, the SEHA hospital network, Sheikh Shakhbout Medical City, SEHA Clinics and the PureLab, Rafed and One Health service businesses.
Read against that portfolio, the Unilabs carve out is small in scope and consistent in direction: buy the missing layer of an existing asset rather than enter a new country. It belongs to the same pattern as other recent outbound moves from the Emirates, from Mubadala’s USD 1 billion minority stake in Luckin Coffee to IHC’s purchase of 80 per cent of Marlan Space.
What it means for business in the UAE
Nothing in this announcement changes a rule, a fee or a procedure. No threshold moves, no licence category opens, and no new filing obligation appears. For companies operating in the Emirates the value of the news is contextual, and it lands in three places.
Outbound deal flow keeps its direction. UAE entities accounted for around 80 per cent of GCC deal value in H1 2026 according to Grant Thornton’s mid year review, and regional dealmakers gather in Dubai for the Private Capital Summit on 15 September 2026. A carve out of a UK laboratory network by an Abu Dhabi listed group is a datapoint in that flow, not a departure from it.
The UK corridor keeps thickening. Britain and the GCC have been moving towards a free trade agreement, a process covered in our note on the UK and GCC trade deal timetable. Companies with a UK arm and a UAE holding company should expect the supplier, clinical and employment side of that corridor to grow faster than the paperwork around it.
Healthcare and life sciences remain an Abu Dhabi priority. The emirate is pulling capability into the sector from several directions at once, including the ADIO agreement with Bayer on life sciences and agrifood. Suppliers of laboratory equipment, reagents, logistics and clinical software have a larger addressable customer inside the UAE than the headline about London suggests.
Practical checklist
- No action is required from UAE companies as a result of this announcement. There is no deadline, no registration and no filing attached to it.
- Suppliers to PureLab or Circle should watch for procurement consolidation: an integrated diagnostics model usually means fewer, larger contracts rather than more of them.
- Companies structuring a UK arm from the UAE should separate the holding question from the operating question early, because licences and clinical accreditations do not travel with a share transfer automatically.
- Groups planning a carve out in either direction should map contracts, licences and staff before the term sheet, since selected operations deals stand or fall on that list.
- Investors in ADX healthcare names should treat the release as a capability announcement: without a price and a completion date it carries no near term earnings figure.
How Atlant Capital can help
Cross border expansion of this kind starts with an ordinary set of corporate steps in the Emirates, and that is the part we run. We register companies on the mainland and in the free zones, including holding structures used to own foreign subsidiaries, and our guide to company formation in the UAE sets out how the choice of jurisdiction shapes everything that follows. Details of the service itself are on our company setup page.
We prepare the KYC package and the source of funds file for corporate and personal bank accounts, we handle legalisation of foreign documents for use in the UAE, and we arrange residency and work visas for founders and staff relocating into the country. Accounting, audit, VAT and corporate tax filings are handled by licensed accounting firms in our partner network. Valuation, transaction terms, legal due diligence and clinical regulatory work stay with the specialist advisers on each side of a deal.
What to watch next
Three things would turn this announcement into a measurable event. First, a completion notice with a date, which would establish when the laboratories actually change hands. Second, any disclosure of consideration in PureHealth’s next set of results, which would size the deal. Third, the treatment of the more than 90 external clients after the transition, which is the clearest indicator of whether the network is being run as a service business or as an internal cost centre for Circle hospitals. Until then, the verifiable content of the news is the perimeter, the parties and the client base.
Source: Gulf News.
FAQ
What did PureHealth actually buy in the United Kingdom?
PureHealth did not buy a company. Its UK subsidiary Circle Health Group is taking over selected laboratory operations and infrastructure from Unilabs Limited, including two hub laboratories in Euston and Cavendish Square in London and a network of licensed laboratories across the country. The announcement was made on 11 September 2026 and covers operations rather than the Unilabs UK legal entity.
How much did the PureHealth Unilabs deal cost?
The price was not disclosed. The PureHealth release of 11 September 2026 and the Abu Dhabi Media Office statement carrying the same text give no consideration, no completion date and no regulatory conditions. Any figure circulating for this transaction is an estimate rather than a disclosed number.
How many hospitals and clients does the laboratory network serve?
The network will serve Circle Health Group’s more than 50 hospitals in the United Kingdom and will keep serving more than 90 external healthcare clients. Service lines include pathology, histopathology, blood sciences, microbiology and specialist diagnostics. Circle’s existing clinical activity provides laboratory volumes from the start, with further eligible volumes expected to move over time.
Does this change anything for companies operating in the UAE?
No. The announcement changes no law, fee, threshold or procedure in the Emirates, and it creates no deadline or filing obligation. Its relevance is contextual: it is another outbound transaction by an ADX listed group, and it expands the UAE to UK corporate corridor in healthcare. PureLab, the group’s UAE laboratory business, runs more than 150 laboratories and over 25 million tests a year and supplies the operating model for the UK platform.
